Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension
OSCAR
A Phase III, Multicenter, Open-Label, Dose-Titrating, 16-Week Study Evaluating The Efficacy, Tolerability and Safety of Olmesartan Medoxomil 20 Mg and 40 Mg Alone or in Combination With 12.5 Mg to 25 Mg of Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension
1 other identifier
interventional
410
10 countries
31
Brief Summary
Efficacy, tolerability and safety of olmesartan alone or in combination with hydrochlorothiazide in the treatment of mild to moderate essential hypertension
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_3
Started Sep 2005
Shorter than P25 for phase_3
31 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 29, 2005
CompletedFirst Posted
Study publicly available on registry
August 31, 2005
CompletedStudy Start
First participant enrolled
September 1, 2005
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2006
CompletedDecember 5, 2018
December 1, 2018
August 29, 2005
December 3, 2018
Conditions
Outcome Measures
Primary Outcomes (1)
Efficacy of olmesartan alone or in combination with hydrochlorothiazide in the treatment of mild to moderate essential hypertension
Secondary Outcomes (1)
Safety and tolerability of olmesartan alone or in combination with hydrochlorothiazide in the treatment of mild to moderate essential hypertension
Interventions
Eligibility Criteria
You may qualify if:
- Subject has mild to moderate hypertension
You may not qualify if:
- History of secondary hypertension
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Pfizerlead
Study Sites (32)
Pfizer Investigational Site
Medellín, Antioquia, Colombia
Pfizer Investigational Site
Barranquilla, Atlántico, Colombia
Pfizer Investigational Site
Cartagena, Atlántico, Colombia
Pfizer Investigational Site
Bogota, Cundinamarca, Colombia
Pfizer Investigational Site
Cali, Valle del Cauca Department, Colombia
Pfizer Investigational Site
Escobedo, Guayas, Ecuador
Pfizer Investigational Site
Quito, Pichincha, Ecuador
Pfizer Investigational Site
NT, Hong Kong
Pfizer Investigational Site
Shatin, NT, Hong Kong
Pfizer Investigational Site
Jakarta, 10430, Indonesia
Pfizer Investigational Site
Jakarta, 11420, Indonesia
Pfizer Investigational Site
Jakarta, Indonesia
Pfizer Investigational Site
Surabaya, 60286, Indonesia
Pfizer Investigational Site
Seremban, Negeri Sembilan, 70300, Malaysia
Pfizer Investigational Site
Kuching, Sarawak, 93586, Malaysia
Pfizer Investigational Site
San Juan City, National Capital Region, Philippines
Pfizer Investigational Site
Quezon, Philippines
Pfizer Investigational Site
Singapore, 119074, Singapore
Pfizer Investigational Site
Singapore, 169608, Singapore
Pfizer Investigational Site
Guei-Shan Shiang, Tau-Yuan Shian, 333, Taiwan
Pfizer Investigational Site
Kaohsiung City, 813, Taiwan
Pfizer Investigational Site
Taipei, 106, Taiwan
Pfizer Investigational Site
Taipei, 112, Taiwan
Pfizer Investigational Site
Khet Rajathevee, Bangkok, 10400, Thailand
Pfizer Investigational Site
Bangkok, 10400, Thailand
Pfizer Investigational Site
Bangkok, 10700, Thailand
Pfizer Investigational Site
Chiang Mai, 50200, Thailand
Pfizer Investigational Site
Bornova/Izmir, 35100, Turkey (Türkiye)
Pfizer Investigational Site
Haseki/Istanbul, 34390, Turkey (Türkiye)
Pfizer Investigational Site
S¿hhiye/Ankara, 06100, Turkey (Türkiye)
Pfizer Investigational Site
Sihhiye/Ankara, 06100, Turkey (Türkiye)
Pfizer Investigational Site
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Pfizer CT.gov Call Center
Pfizer
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
August 29, 2005
First Posted
August 31, 2005
Study Start
September 1, 2005
Study Completion
July 1, 2006
Last Updated
December 5, 2018
Record last verified: 2018-12